THE SINGLE BEST STRATEGY TO USE FOR LINSITINIB SIDE EFFECTS

The LIDS trial fulfilled its Main endpoint with statistical significance for the 150mg BID dose. Linsitinib With this trial validated the protection profile found while in the prior oncology studies and importantly demonstrated a good security profile on critical adverse situations (AEs) of interest for the IGF-1R focus on for instance hearing impa